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ABSTRACT
Tefinostat (CHR-2845) is a novel monocyte/macrophage-targeted histone 
deacetylase (HDAC) inhibitor which is cleaved into its active acid by the intracellular 
esterase human carboxylesterase-1 (hCE-1). The in vitro efficacy of tefinostat was 
characterised in cell lines and in a cohort of 73 primary AML and CMML samples.  
Dose-dependent induction of apoptosis and significant growth inhibitory effects were 
seen in myelomonocytic (M4), monocytic/monoblastic (M5) and CMML samples in 
comparison to non-monocytoid AML sub-types (p = 0.007). Importantly, no growth 
inhibitory effects were seen in normal bone marrow CD34+ cells exposed to AML-toxic  
doses of tefinostat in clonogenic assays. Expression of hCE-1 was measured by 
intracellular flow cytometry and immunoblotting across the cohort, with highest 
levels seen in M5 AML patients. hCE-1 levels correlated with significantly increased 
tefinostat sensitivity (low EC50) as measured by growth inhibition assays (p = 0.001) 
and concomitant elevation of the mature monocytoid marker CD14+. Strong induction 
of intracellular histone protein acetylation was observed in tefinostat-responsive 
samples, as were high levels of the DNA damage sensor γ-H2A.X, highlighting 
potential biomarkers of patient responsiveness. Synergistic interaction between 
tefinostat and the current standard treatment cytarabine was demonstrated in dose 
response and clonogenic assays using simultaneous drug addition in primary samples 
(median Combination Index value = 0.51). These data provide a strong rationale for 
the further clinical evaluation of tefinostat in monocytoid-lineage haematological 
neoplasms including CMML and monocyte-lineage AMLs.
INTRODUCTION
Monocytoid-lineage leukaemias encompass the 
monocytoid subtypes of acute myeloid leukaemia (AML) 
(acute myelomonocytic leukaemia [previously FAB 
type M4] and acute monoblastic/monocytic leukaemia 
[M5]), as well as chronic myelomonocytic leukaemia 
(CMML) and juvenile myelomonocytic leukaemia 
(JMML) [1, 2]. Although the overall prognosis of AML 
has improved gradually over the last 40 years, the majority 
of patients continue to succumb to the disease with clinical 
prospects remaining particularly bleak for older patients; 
there has been little change to standard chemotherapeutic 
treatment approaches over this time [3]. CMML is 
a neoplasm that is classified within the WHO sub-
categorisation of ‘myelodysplastic / myeloproliferative 
neoplasms’ [2] that has a high median age of presentation 
(70–75 years), a median survival of only 11–17 months 
and currently very limited treatment options [4, 5]. 
There is a pressing need to exploit advances made in 
the understanding of the pathogenetic mechanisms that 
underpin monocytoid malignancies by developing novel 
therapeutic agents, applicable ideally to the treatment of 
patients of all ages, that are able to effectively deliver 
targeted effects to malignant cell populations while 
avoiding significant systemic toxicity.
Histone acetylation is an important molecular 
modification used to regulate gene transcription 
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that affects many cellular processes including cell 
proliferation, differentiation, DNA repair, cell survival 
and angiogenesis [6–8]. Histone deacetylases (HDACs) 
are a family of epigenetic modifiers that alter chromatin 
structure by removing lysine acetylation from histones, 
resulting in a transcriptionally-closed state and subsequent 
gene silencing or loss of expression. Alterations in 
epigenetic programming have been commonly reported in 
the initiation, progression and maintenance of cancer; and 
aberrant localization of HDACs and resultant promoter 
silencing has been implicated in several malignancies [7, 9] 
including AML and the myelodysplastic syndromes 
(MDS) [10–12] and has been reported in connection with 
common oncogenic fusion proteins such as AML1ETO 
(t8:21), and Inv16 (core binding protein) abnormalities 
[13]. Myelomonocytoid and monocytoid / monoblastic 
AML (FAB M4 and M5) accounts for approximately 25% 
of total AML cases [44]; these cases have a distinct clinical 
profile with frequent extramedullary manifestations 
and leucocytosis along with emerging associations with 
abnormalities in epigenetic regulation in the form of 
DNMT3A mutations [45, 46].
Given the reversible nature of acetylation 
modifications, therapeutic targeting of HDACs has 
been an active area of drug development with the 
promise of correcting the effects of aberrant gene 
expression [14]. HDAC inhibitors may exert their 
activity by multiple mechanisms of action including: cell 
differentiation, DNA repair inhibition [15], induction 
of reactive oxygen species [16], and replication 
stalling [17]. Clinical trials of several HDAC inhibitors 
including valproic acid, vorinostat, romidepsin, 
belinostat and panabinostat have been conducted in 
both solid tumours and haematological malignancies 
including AML, MDS and CMML patients [18–22]. 
In general, reported clinical responses to single-agent 
HDAC inhibitory therapy have been modest with dose 
escalation of HDAC inhibitors being limited by a 
relatively restricted therapeutic window. Off-target effects 
of HDAC inhibition have been associated with significant 
systemic toxicities including gastrointestinal disturbances, 
thrombocytopenia, fatigue and insomnia which have 
limited the wider clinical uptake of these agents. It is 
highly desirable to develop mechanisms through which 
HDAC inhibitory activity can be more-selectively 
concentrated within tumour cells while sparing non-disease 
cell populations. 
Tefinostat (CHR-2845) is a novel pan HDAC 
inhibitor which is cleaved to an active acid, CHR-2847, 
by the intracellular esterase human carboxylesterase-1 
(hCE-1), the expression of which is limited to cells of 
monocytoid lineage and some hepatocytes, allowing 
selective accumulation of active drug within monocytoid 
cells. [23]. A phase I dose escalation study of tefinostat 
in patients with relapsed/refractory haematological 
malignancies demonstrated early signs of clinical efficacy 
without any dose limiting toxicity. [23].
We examined the pre-clinical activity of tefinostat 
in a large cohort of primary AML and CMML patient 
samples in order to assess lineage specific activity, 
potential therapeutic window and combination studies 
with Cytarabine to build a rationale for future therapeutic 
evaluation in monocytoid leukaemias.
RESULTS
Monocytoid leukaemias show selective high 
sensitivity to tefinostat
The in vitro efficacy of tefinostat was first assessed 
by MTS cell viability assay in AML cell lines HL60 
(M2 FAB type), MV411 (M4, FLT3-ITD), OCIAML3 
(M4 NPM1mut) and THP1 (M5) (EC50 = 2300 nM +/−226 
vs. 57 nM +/−6.2 vs. 110 nM +/− vs. 560 nM +/−17.12 
respectively, Figure 1A). Annexin V/PI incorporation 
showed strong apoptotic induction in myelo-monocytic 
cell lines THP1, MV411 (FLT3-ITD) and OCIAML3 
within 24 hours of tefinostat treatment that was only 
reached in non-monocytic HL60 cells at much higher 
drug concentrations (Figure 1B–1C). Dose response to 
tefinostat was assessed in a cohort of 66 primary AML 
and 7 primary CMML samples (Ave EC50 2.7 µM +/− 3.1). 
Significant growth inhibitory effects were seen in M4 
(myelomonocytic)/M5 (monocytic / monoblastic) AMLs 
and CMML samples with lower EC50s in comparison 
to non-M4/M5 AML FAB types (mean EC50 M4/M5 
= 1.1 µM +/−1.8, CMML = 1.9 +/−1.6 vs. M0/M1 = 5.1 µM 
+/−4.7 respectively, *p = 0.009 spearman’s correlation, 
Figure 1D). This selectivity between M0/M1 and M4/M5 
FAB groups was abolished when the t-butyl tefinostat 
analogue CHR-8185 (which is not cleaved by hCE-1) was 
substituted as an alternative HDACi, further supporting 
the monocytoid selectivity of tefinostat.  M2 FAB type 
AMLs displayed a wide range of sensitivity of response 
to tefinostat; overall responses of M2 samples were not 
significantly different from the M4/M5 sub-groups. 
Importantly, there was no differential response between 
tefinostat and CHR8185 in the M2 subgroup, suggesting 
responses to be non hCE-1 mediated in this group 
(Figure 1D).
Further analysis of the relationship between in vitro 
tefinostat sensitivity (log10(EC50) and patient characteristics 
revealed no significant differences in drug efficacy 
according to other disease parameters including clinical 
outcome, presenting cytogenetics and FLT3/NPM1 
mutational status.(Supplementary Table S1).
Monocytic targeting of HDACi therapy spares 
normal bone marrow progenitor cells
Analysis of selective response to tefinostat in 
sub-populations of primary cells was carried out using 
flow cytometric 7AAD exclusion assays. CD14+ AML 
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Figure 1: Monocytoid leukaemias show selective high sensitivity to Tefinostat. (A) Dose response plot for AML cell lines 
HL60 (M2), MV411 (M4), OCIAML3 (M4) and THP-1 (M5) treated with serial dilutions of Tefinostat. Tefinostat-induced Annexin 
V/PI incorporation measured by flow cytometry in THP1, MV411, OCIAML3 and HL60 at (B) 24 Hrs and (C) 48 Hrs post treatment. 
(D) Box and whiskers plots showing range of FAB type-specific MTS-derived EC50s in response to Tefinostat and the comparative non 
hCE-1-dependent t-butyl analogue CHR8185 in a cohort of 66 primary AML and 7 primary CMML samples. (Tefinostat EC50 M4/
M5/CMML vs. M0/M1 *p = 0.009 spearman’s correlation. Tefinostat vs. t-butyl analogue CHR8185, only significant in M4/M5 groups 
ǂp < 0.007).
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blasts were highly sensitive to tefinostat treatment in 
contrast to CD34+/CD14− AML blasts and CD45high 
lymphocyte populations (Figure 2A). This sensitivity was 
significantly reduced in when equivalent concentrations 
of the non-hCE-1-dependent analogue CHR8185 were 
used, demonstrating the myelo-monocytic specificity 
of Tefinostat (Supplementary Figure S1). Importantly, 
no growth inhibitory effects were seen in normal bone 
marrow (NBM) CD34+ cells exposed to AML-toxic 
doses of tefinostat while, in comparison, equivalent 
concentrations of CHR-8185 caused considerable 
cytotoxicity (Figure 2B). Exposure of NBM progenitor 
cells to increasing concentrations of tefinostat in longer-
term colony assays failed to reduce colony forming 
units in comparison to vehicle-treated controls and AML 
treated samples (pre-selected for high CD14+ percentage), 
which showed significant reduction in colony formation 
(Figure 2C, p < 0.02).
hCE-1 expression levels dictate efficacy of 
tefinostat in monocytic leukaemias
hCE-1 expression in primary samples was quantified 
by intracellular flow cytometry in combination with 
cell surface markers CD14, CD64 and CD45 to allow 
identification of hCE-1 levels in different cellular sub-
populations (Supplementary Figure S2). Significant 
correlation was seen between levels of the mature 
monocytic marker CD14+ and hCE-1 expression in 
AML samples (Figure 3A). Further analysis of a larger 
cohort of 40 primary AMLs and 7 CMMLs by western 
blot confirmed highest hCE-1 levels in myelomonocytic 
and monocytic FAB types, with M5 AMLs displaying 
significant overexpression in comparison to NBM 
levels (Figure 3B–3C, p = 0.01). This observation was 
validated by microarray analysis of hCE-1 mRNA in a 
further 130 AML samples, with M4/M5 AMLs showing 
significant overexpression compared to NBM CD34+ cells 
(Supplementary Figure S3). High hCE-1 levels was 
associated with low EC50 values to tefinostat across 
the cohort as measured by western blotting (Figure 3D 
p < 0.001). To supplement western blot expression levels, 
intracellular flow analysis of hCE-1 in a smaller cohort of 
M2, M4 and M5 monocytoid AML samples was divided 
into tefinostat-sensitive primary AMLs (EC50 < 1 µM 
Ave) and  tefinostat-resistant samples (EC50 > 2.5 µM). 
Significantly higher intracellular flow levels of hCE-1 
were observed in tefinostat-sensitive AMLs compared to 
resistant samples (Figure 3E p < 0.001).
Increases in intracellular acetylation and DNA 
damage induction are biomarkers of tefinostat 
efficacy
In order to identify biomarkers of tefinostat 
sensitivity in AML blasts we undertook sub-population 
analysis by flow cytometry to look for differential effects 
on intracellular acetylation. CD14-expressing cells showed 
a maximum induction of intracellular protein acetylation 
at nanomolar tefinostat concentrations after 6 hours of 
drug exposure (Figure 4A). This analysis was extended 
to compare tefinostat sensitive (n = 8, EC50 < 1 µM) and 
resistant AML samples (n = 5, EC50 > 2.5 µM); significant 
acetylation was induced at low nanomolar doses in low 
EC50 samples, but was absent in those patients with 
resistance to tefinostat (Figure 4B). Strong acetylation 
induction was also observed in several CMML patient 
samples (Figure 4C), although this appeared to be less 
variable with Tefinostat sensitivity. Tefinostat-sensitive 
samples also showed strong phosphorylation induction of 
the cell cycle arrest and DNA double strand break damage 
sensor protein γ-H2A.X, which is associated with DNA 
cleavage during apoptosis. Induction was seen within 
24 hours of drug treatment (Figure 4D–4E); suggesting 
γ-H2A.X may be a potential future biomarker of patient 
responsiveness to this drug. 
Tefinostat is synergistic with cytarabine
To further inform clinical development of tefinostat 
we investigated the synergistic potential between tefinostat 
and the conventional cytotoxic agent cytosine arabinoside 
(AraC) at a fixed ratio of 1:10 (Tefinostat:AraC). In vitro 
synergy was demonstrated in combination experiments 
with clinically-relevant concentrations of tefinostat and 
cytarabine (AraC) firstly in MV411 cells (Figure 5A) 
and then in primary AML blasts (Figure 5B, Mean AML 
combination index (CI) = 0.51, n = 31 patient samples, 
Mean CMML CI = 0.53, n = 6 samples, CI at 50% fraction 
affected; values < 0.9 = synergistic, 0.9–1.2 additive, 
> 1.2antagonistic)). This synergism was observed across 
a range of drug effects (Figure 5C and Supplementary 
Table 3). Sequential administration of AraC followed by 
tefinostat did not increase synergistic effects beyond those 
observed with simultaneous application of the two agents 
(Figure 5D–5E); pre-treatment with tefinostat, however, 
was found to antagonise the combination response. 
Interestingly, tefinostat-responsive AMLs frequently 
stimulated NFκB p65 levels, commonly associated with 
drug resistance mechanisms, although these samples 
showed good synergy in combination with AraC 
(Supplementary Figure S4). Clonogenic assessment 
of single and combination pulse-treated AML blasts at 
an optimum ratio of 1:10 (Tefinostat: AraC) revealed a 
significant reduction in colonies in combination assays 
compared to with each agent used alone (p < 0.04).
DISCUSSION
Although overall survival rates in AML have 
improved gradually over the last four decades this has 
been achieved largely through incremental improvements 
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Figure 2: Monocytic targeting of HDACi therapy spares normal bone marrow progenitor cells. (A) Flow cytometric 
analysis of viability of cell subpopulations in primary AML samples in response to Tefinostat dosing measured by 7AAD exclusion (n = 8). 
(B) Dose response effects of Tefinostat and CHR8185 in NBM cells (n = 4) measured by 7AAD exclusion. (C) Tefinostat effects on Colony 
forming units (CFUs) in NBM CD34+ cells (no significant difference, n = 4) and primary AML blasts (*p < 0.02 MWU, n = 6) following 
14 days culture on methocult.
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in supportive care and stem cell transplantation strategies 
with very little change in standard chemotherapy strategies 
over this time; minimal impact has been seen in clinical 
outcomes for older patients who represent the majority 
of newly-diagnosed cases. Similarly in CMML, a 
disease with an even higher median age of presentation, 
there is a considerable unmet need for non-toxic 
therapeutic strategies that are capable of altering the 
natural history of the disease. There is a strong pre-clinical 
rationale for HDAC inhibition in haematological 
Figure 3: hCE-1 expression levels dictate efficacy of Tefinostat in monocytic leukaemias. (A) Correlation plot of CD14+ 
expression vs. hCE-1 mean fluorescence measured by intracellular flow in primary AML samples (n = 10) (B) Representative western blot 
of hCE-1 expression in NBM, AML and CMML patient samples. (C) Comparison of hCE-1 protein levels across FAB types (NBM vs. M5 
*p = 0.01 Wilcoxon rank sum). (D) Correlation plot of hCE-1 protein levels measured by western blot (fold change relative to NBM levels, 
n = 3) compared to tefinostat sensitivity (EC50) in a cohort of 40 primary AML and 7 CMML samples, p = 0.001 Spearman’s correlation per 
10 fold increase in EC50). Dotted box represents low EC50 samples. (E) Monocytoid intracellular hCE-1 levels in tefinostat-sensitive and 
tefinostat-resistant primary samples gated by CD14+/CD64+ (EC50 high (n = 6) and low patients (n = 11), **p < 0.001 MWU).
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Figure 4: Increases in intracellular acetylation and DNA damage induction are biomarkers of Tefinostat efficacy. 
(A) Tefinostat dose-dependent intracellular acetylation staining in a representative primary AML sample using acetylated lysine monoclonal 
antibody and sub-population analysis by flow cytometry. (B) Acetylation induction in Tefinostat sensitive (low EC50/CD14+ black bars, 
n = 8) compared to insensitive (high EC50, white bars, n = 5) primary AML samples, *p < 0.05, **p < 0.005. (C) Tefinostat dose-dependent 
intracellular acetylation induction in primary CMML samples (n = 3). All samples exhibit > 80% CD14+ and > 70% hCE-1 expression. 
(D) Representative western blot of phospho-H2A.X induction by tefinostat at 1 and 24 hours post-treatment. (E) Western blot quantification 
of dose-dependent tefinostat-induced γ-H2A.X induction at 24 hrs compared to vehicle treated control (n = 9 AML samples, *p < 0.01 
Kruskal Wallis).
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Figure 5: Tefinostat is synergistic with Cytarabine. (A) Dose response curves for MV411 cells treated both singly and in combination 
for Tefinostat and AraC (dose ratio 1:10, Tefinostat:AraC). (B) Synergy analysis of tefinostat and AraC displayed as combination index 
(CI) values at EC50 dose affected at an optimal ratio of 1:10 (Tefinostat:AraC) in primary patient samples set up in triplicate (AML Mean 
combination index (CI) = 0.51, n = 31, CMML mean CI = 0.49, n = 5). (C) Representative CI response plot from primary AML showing 
CI values across a range of dose effects (fraction affected). Dose response curves for simultaneous and sequential dosing of drugs in 
(D) OCIAML3 and (E) MV411 cell lines. (F) Clonogenic assessment of synergy interaction in primary AML blasts (n = 4) following single 
agent and 1:10 ratio combination pulse treatment (*p < 0.04 MWU, between both single agents and combination colony growth).
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malignancies, but systemic toxicities including 
gastrointestinal disturbances, myelosuppression, fatigue 
and insomnia have so far hindered the clinical update of 
HDAC inhibitors.
Here we report a series of in vitro experiments in 
which we confirm the monocytoid-lineage specificity 
of tefinostat in leukaemic cells obtained from patients 
with AML and CMML. We observed a dose-dependent 
induction of apoptotic response in myelo-monocytic 
cell types and a significantly greater drug sensitivity at 
sub-micromolar concentrations in this group compared 
to that seen in undifferentiated or non-monocytic patient 
samples. Esterase Sensitive Motif-mediated targeting 
of tefinostat and the resulting CHR-2847 accumulation 
in these cell types resulted in a 3.5–6.5 fold increase in 
anti-proliferative potency compared to the that seen using 
the untargeted t-butyl tefinostat analogue CHR-8185, in 
line with the previously-reported improved efficacy of 
tefinostat in comparison with other ‘non-targeted’ HDAC 
inhibitors such as vorinostat [23]. Lesser responses to 
tefinostat were seen in undifferentiated AML patient 
subgroups M0/M1; although sensitivity was observed in 
occasional undifferentiated samples with inherent HDAC 
inhibitor sensitivity this manifested as equal sensitivity 
to tefinostat and CHR-8185. Similarly, responses in 
M2 subtypes were variable and this correlated with 
the diversity of cellular sub-populations and CD14+ 
expression seen within this group.
Although mechanisms of action of HDAC inhibitors 
remain to be fully characterised, sensitivity to these agents 
has been linked to the apoptotic capability of each cell 
type. Differing combinations of apoptotic mediators, cell 
cycle abnormalities and differentiation blocks between 
patient samples make it difficult to predict cellular 
outcome to HDAC inhibitor treatment, although previous 
studies have shown that monocytic AML cell types such as 
the M5 cell line THP1 have greater apoptotic sensitivity to 
the HDAC inhibitor vorinostat than other non-monocytic 
AML cell lines [24]; this has been potentially linked to 
activity of Bcl-2 family members [25]. Previous studies of 
the HDAC inhibitor panobinostat have shown induction of 
growth arrest and increase in myeloid transcription factor 
expression associated with differentiation in AML cells 
[26]. We found, however, that tefinostat induces apoptosis 
at sub- EC50 level doses, indicating a different mechanism 
of action to that of panobinostat. Other potential 
mechanisms of action include acetylation and degradation 
of key chaperone molecules such as HSP90 [27] which 
supports a multitude of leukaemic oncoproteins. We find 
total HSP90 protein levels to be unaffected by tefinostat 
exposure in primary AML cells (data not shown), although 
this does not exclude the possibility of a functional change 
in HSP90 activity.
High levels of hCE-1 expression were found to drive 
a significant increase in tefinostat efficacy as measured by 
growth inhibition assays (p = 0.001), and also strongly 
correlated with expression of the mature monocytoid 
marker CD14+. CD14+ is widely used to define a mature 
monocytic cell type; we and others find, however,  that 
CD14 may also be low or absent from leukaemic 
monocytes as part of the heterogeneity associated with 
this disease [28]. We observed that whilst, in the majority 
of patients, CD14 levels correlated  with increased hCE-1 
expression, this was not exclusive, particularly in M2 
AMLs where, as previously reported, high hCE-1 levels 
were occasionally observed in the absence of significant 
CD14 expression [29]. 
Induction of intracellular H3/H4 histone acetylation 
was observed in all tefinostat-responsive AML and 
CMML patient samples in contrast to previous studies 
where other agents such as entinostat, vorinostat and 
panabinostat induced only modest levels of H3/H4 
acetylation and monocytic populations were found to 
be resistant to HDAC inhibitory treatment [23, 30, 31]. 
hCE-linked targeting of tefinostat appears to circumvent 
this issue, with CD14+ monocytic AML sub-populations 
and CMML patient samples, as expected, showing the 
highest levels of drug response. Additionally, we observed 
preservation of normal bone marrow CD34+ cells and 
clonogenic function at AML-toxic doses of tefinostat in 
contrast to other HDAC inhibitors used in similar studies 
where significant increases in acetylation were observed 
in normal CD34+ cells [32, 33]. This finding emphasises 
the potential for limiting off-target systemic toxicities by 
harnessing hCE-1-dependent HDAC inhibitory activity 
in malignancies involving cells of monocytoid lineage 
(AML-M4, AML-M5 and CMML). 
As yet a strong correlation between hyperacetylation 
and clinical response to HDAC inhibitors remains to 
be fully established. HDAC inhibitory efficacy is also 
reported to be dependent on accumulation of DNA damage 
[15], replication stalling [17], and apoptotic induction 
[34]. AML cases with leukaemia- associated fusion 
proteins are DNA damage repair deficient and therefore 
may be more resistant to HDAC inhibition [35]. We found 
no association, however, between tefinostat sensitivity 
and any patient characteristics such as cytogenetic 
group. We demonstrated that tefinostat induces the DNA 
damage marker γ-H2A.X in the majority of responsive 
patient samples similarly to that reported for other HDAC 
inhibitors such as vorinostat [36], suggesting that this may 
be a potential biomarker of patient response. Our data 
suggest that tefinostat induces both apoptosis and DNA 
damage accumulation within 24 hours of treatment in a 
majority of samples which may predict greater clinical 
response to this HDAC inhibitor. HDAC inhibition has 
also previously been demonstrated to signal pro-survival 
pathway feedback in the form of hyperacetylation of 
p65 NFκB signalling [37]; dual inhibition of HDAC and 
NFκB may potentiate efficacy in AML [38]. We observed 
a transient increase in NFκB p65 induction following 
tefinostat treatment, although this did not appear to impair 
γ-H2A.X or apoptotic induction in our sample cohort. 
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Another putative mechanism of action of HDAC 
inhibitors in single and combination studies is that of 
oxidative injury [16, 37, 39], This process is driven through 
NOX-mediated ROS induction which has been shown by 
our group to be constitutively active in myelomonocytic 
AML subtypes [40], and which may, in part, contribute to 
the greater efficacy of tefinostat in these patients. Although 
HDACis have been previously reported to selectively 
target FLT3 ITD-mutant proteins for degradation in AML 
[41] and to enhance FLT3 inhibition in cell lines [42, 43], 
we found no association between in vitro sensitivity to 
tefinostat and FLT3-ITD mutation status in our primary 
sample cohort (Supplementary Table S1). 
As HDAC inhibition may result in a reduction of 
cells in S-phase, concerns have arisen that combination 
with traditional chemotherapeutic agents such as AraC 
may be antagonistic and that sequential administration 
may be required to optimise response [30, 37]. Our 
combination studies suggested that simultaneous dosing 
with tefinostat and AraC may be the most effective 
therapeutic regime and clonogenic synergy assays suggest 
this combination is also capable of targeting proliferative 
subsets within monocytoid AMLs. Pre-dosing with AraC 
did not significantly improve efficacy of the combination 
studies and pre-treatment with tefinostat produced an 
antagonistic response. Primary AML blasts demonstrated 
consistently high degrees of synergy in all primary samples 
tested (CI = 0.5, n = 36). This synergistic interaction with 
AraC (a principal component of AML cytotoxic regimens 
for many years) warrants further larger scale evaluation as 
a prelude to formal clinical evaluation.
The effective in vitro targeting of HDAC inhibition 
in monocytoid AML and CMML described above, 
combined with encouraging early signs of clinical activity 
(coupled to selective HDAC inhibition) in the absence 
of tefinostat-related toxicity in the Ossenkoppele study, 
provides a compelling case for further clinical evaluation 
of tefinostat in larger studies in monocytoid-lineage 
leukaemias. Rapid identification of suitable ‘monocytoid’ 
patients at diagnosis will present some challenges for trial 
design and will place an emphasis on close interactions 
between laboratory and clinic. Of the two CMML patients 
treated in the phase I study, one achieved a bone marrow 
complete response (CR) at relatively small doses and 
moving forward MONOCLE, a single- arm phase 2 study 
of tefinostat monotherapy in CMML (EudraCT 2015-
002281-23) is shortly to commence recruitment at sites 
within the UK.
METHODS
Cell culture reagents and patient samples
AML samples were collected with informed consent 
from newly-diagnosed patients entering UK NCRI 
AML15, 16 and 17 studies (Ethics Reference Numbers 
2005-001149/40, 2005-002847/14, 2007-003798/16) 
(Supplementary Tables S1 and S2) in accordance with 
the Declaration of Helsinki. CMML samples were 
obtained with informed consent under the MDSBio 
Sample Collection Study (Ethics Reference Number 06/
Q1606/110). Mononuclear cells were purified by Ficoll 
density gradient followed by CD45 staining (AML 
samples with < 70% blast content following purification 
were excluded from further analysis). AML/CMML cells 
were cultured in IMDM (Sigma) with 10% FCS (Biosera). 
Normal bone marrow MNCs were purchased from Lonza 
and CD34+ cells were isolated using MiniMACS CD34 
columns (Miltenyi Biotec) according to the manufacturer’s 
instructions.  HL60, MV411, OCIAML3 and THP-1 
cell lines were cultured as recommended by ATCCLGC 
(http://www.lgcstandardsatcc.org). All cultures were 
incubated at 37°C, 5% CO2. Tefinostat (CHR-2845) and 
its N-butyl analogue control CHR8185 were supplied by 
Chroma Therapeutics (Abingdon, UK). Cytarabine was 
obtained from Sigma.
Western blot analysis
Sample preparation of lysates and western blotting 
was performed as previously described [47]. Blots were 
probed with: γ-H2A.X Ser139 (Cell Signalling), hCE-1 
(Lifespan biosciences). Equal loading was confirmed by 
Actin (Abcam).  Quantification of proteins was carried out 
using AIDA image analyser v4.22 (Raytest, Straubenhardt, 
Germany).
Drug response and cell viability assays
In vitro cell survival/drug response assays were 
set up with serial dilution of drugs in 96 well plates with 
8 × 104 cells per well. Cell viability was assessed by Cell 
Titre 96 Aqueous One MTS reagent (Promega) at 48 Hrs 
according to the manufacturer’s instructions. Samples with 
less than 70% viability at 48 hours in untreated samples 
were excluded from analysis. For cytosine arabinoside 
(AraC) synergy experiments, dose response assays were 
set up in triplicate for single and fixed ratio combination 
treated AML cell lines and primary samples using 
clinically-relevant AraC concentrations. For sequential 
drug dosing cells were pre-treated for 24 Hrs with either 
Tefinostat or AraC prior to addition of the second drug. 
For sub-population analysis of drug response assays, 
cells were harvested after 48 h, surface stained with 
anti-CD45, CD14, CD64 and resuspended in 1 µg/ml 
7aminoactinomycin D (7AAD) to determine viable cells 
remaining by flow cytometry using a FACSCalibur® 
cytometer (BD Biosciences, Oxford, UK).  Triplicates 
were averaged and dose response curves inputted to 
Calcusyn to generate EC50 and combination index values 
(Calcusyn v2.0 software,Biosoft, Cambridge, UK). 
Annexin V positivity was measured using the Annexin 
V Apoptosis Detection Kit (eBioscience, Hatford, UK) 
according to the manufacturer’s instructions. 
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Intracellular flow cytometry 
Cells were prestained for 20 min with surface 
markers CD14, CD64, CD45 (BD Biosciences), then fixed 
in phosflow lyse buffer (BD biosciences) for 10 mins at 
37°C before washing (PBS/0.5%BSA/0.1 NaAzide) and 
permeabilising in phosflow permeabilisation buffer II 
(BD biosciences) for 30 mins on ice. Primary antibodies 
were added for 45 mins at room temperature (RT) 
anti-hCE-1 (Lifespan biosciences LS-105283) or 
IgG control (Novous biological NB810-56910). For 
assessment of modulation of intracellular acetylation, cells 
were pre- incubated for 6 hours with Tefinostat prior to 
surface staining and fixation. Primary antibody Ac-k-103 
(Cell signaling #9681) and IgG control (Mouse IgG2a 
×0943 DAKO) were used at 200 ng/ml. Finally, cells 
were washed twice and incubated for 45 mins at RT with 
PE conjugated secondary antibodies goat-anti-rabbit or 
goat-anti-mouse (hCE-1 and Ak-k-103 respectively) prior 
to FACS analysis.
Colony assays
CD34+ NBM cells and AML samples with > 70% 
CD14+ were plated in triplicate at 1 × 103 (NBM) and 5 × 104 
(AML) cells per dish in semi-solid medium (Methocult 
Optimum H4034, Stem Cell Technologies, Location) in 
the presence of increasing doses of Tefinostat or vehicle 
control and cultured for 14 days at 37°C, 5% CO2  prior to 
colony counting. For synergistic assays, AML blasts were 
pulse treated with single agent (1 µM tefinostat, 10 µM 
AraC) or a 1:10 ratio (Tefinostat:AraC) prior to plating 
out in methocult.
Statistical analysis
Multivariable analyses were performed using either 
logistic or Cox’s proportional hazard regression methods 
adjusted for age, white blood cell count, cytogenetic 
group, performance status, de novo/secondary disease and 
sex. For all other results, differences between mean values 
were compared by Minitab v13 (Minitab Inc. PA, USA) 
using Mann WhitneyU or paired t-test.
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